Mineralogical analysis of the respiratory tract in aluminium oxide-exposed workers

C. Voisin*, F. Fisekci$, B. Buclez†, A. Didier‡, B. Couste*, F. Bastien§, P. Brochard*†#, J-C. Pairon*§†#


ABSTRACT: A retrospective study was conducted in order to characterize the retention of fibrous and nonfibrous mineral particles in the respiratory tract in subjects with previous occupational exposure in the aluminium industry. Bronchoalveolar lavage (BAL) fluid (three samples) or lung parenchyma (two samples) were studied using analytical transmission electron microscopy in five patients. A high concentration of aluminium fibres (>10⁷ fibres·g⁻¹ dry lung) was identified in two lung tissue samples, and aluminium fibres were also identified in BAL fluid in three patients. All fibres were short (mean length: 1–2 μm), with no fibre longer than 5 μm. Some biopersistence of these fibres in the respiratory tract is suggested from these observations, since fibres were identified in biological samples collected more than 4 yrs after cessation of exposure in four out of five patients.

Occupational physicians should be aware of possible exposure to short, thin aluminium fibres during primary aluminium production. Further studies are needed to assess the potential health effects of these fibres. Industrial hygiene measurements should also be performed to document the potential sources of exposure to aluminium fibres in this industry.

worked in the aluminium industry and whose aluminium fibres (fibres containing only aluminium on chemical micro-analysis) were identified in BAL fluid or lung tissue.

Patients and methods

Patients

The subjects included were those for whom a mineralogical analysis of BAL fluid or lung tissue samples using ATEM had been requested in our laboratory between 1990 and 1993, and for whom industrial exposure to aluminium minerals was evident on the basis of the occupational questionnaire. Five patients were identified on the basis of these criteria. For each patient, information was collected about tobacco smoking, presumed diagnosis at the time of request for analysis of the samples, and job history, including dates of beginning and end of each occupation.

Patient No. 1. A nonsmoking 55 year old man, who had worked for 30 yrs in the primary aluminium industry (3 yrs as potline operator with the Söderberg process and 27 yrs as a casthouse operator), was investigated. Pulmonary function tests (spirometry) showed a restrictive syndrome (total lung capacity (TLC) 53% of predicted value). An impairment of carbon monoxide transfer was also noted. The patient had stopped working 4 yrs before undergoing surgery. Histological analysis of a lung biopsy specimen led to the diagnosis of diffuse interstitial fibrosis.

Patient No. 2. A nonsmoking 55 year old man, who had a 28 year history of working in the aluminium smelting industry (Söderberg process), was sent to the emergency unit of a Chest Department with massive haemoptysis. Pneumonectomy was performed and the diagnosis of pseudoneoplastic pulmonary amyloidosis was established. He had stopped working 5 yrs before collection of the lung tissue sample.

Patient No. 3. A nonsmoking 72 year old man, who had a 31 year history of working in an alumina plant (bauxite attack by chemical process), was found to have diffuse interstitial fibrosis on high resolution computed tomography (HRCT). Pulmonary function tests (spirometry) showed a restrictive syndrome (TLC 50% of predicted). An impairment of carbon monoxide transfer was also noted. The patient had stopped working 10 yrs before collection of BAL fluid.

Patient No. 4. A 26 year-old man, who had a 6 month history of working in the aluminium smelting industry as a crushed bath operator, was investigated for dyspnoea at work. He was found to have bronchial hyper-responsiveness confirmed by pulmonary function tests. He stopped working 6 months before collection of the biological sample (BAL fluid). He was a smoker with a cumulative tobacco consumption of 10 pack-yrs.

Patient No. 5. A 68 year old man, who was an ex-smoker (30 pack-yrs) and had worked for 9 yrs sorting scoria derived from an aluminium foundry and 16 yrs sorting various metals, was investigated for dyspnoea and crackles. Chest radiograph and computed tomography (CT) scan showed interstitial opacities. Pulmonary function tests (spirometry) showed a mild restrictive impairment (TLC 79% pred) with no influence on carbon monoxide transfer. The patient had stopped working 2 yrs before collection of the BAL fluid sample.

Particle analysis

Preparation and mineralogical analysis of samples were performed as described previously [20–22]. Briefly, BAL fluid or lung tissue samples were collected in flasks containing 10 mL of 10% formalin. Samples were allowed to react at room temperature for 2 h with freshly filtered sodium hypochlorite until all organic material had been digested. The suspension was then filtered through a membrane filter (Millipore 25 mm, 3 µm pore size) or a carbon-coated polycarbonate membrane (Nucleopore, 0.4 µm pore size) for light microscopic and electron microscopic analysis, respectively. Two samples were analysed for each patient. The first sample allowed quantification of asbestos bodies in the BAL fluid or in dry lung tissue by conventional light microscopy. The second sample was analysed using a transmission and scanning electron microscope (ATEM SCAN JEOL EX II) fitted with an energy dispersive X-ray spectrometer (TRACOR TN 5302). Briefly, three variables were determined for the second sample. Firstly, the numerical concentration of all types of NFMP, expressed per millilitre of BAL fluid or per gram of dry lung tissue, and the relative percentage of different mineralogical species obtained from the analysis of 50 particles in randomly selected fields were determined. Each particle was identified by morphological features, electron diffraction pattern and microanalysis spectrum (allowing detection of elements with atomic number greater than 10). The X-ray spectrum of aluminium shows a major Kα peak at 1,487 eV. Particles containing aluminium were counted regardless of the other associated mineralogical species. As the relative concentration of a given mineralogical species does not reflect total lung load for this mineral, the absolute concentration of particles containing aluminium was calculated for each subject. This variable was obtained both for BAL fluid samples and lung tissue samples as follows: absolute aluminium concentration=total numerical concentration of all particles (per mL of BAL fluid or per gram of dry lung tissue) × percentage of particles containing aluminium (in BAL fluid or lung tissue). This variable was considered to be a good estimate of the load of aluminium-containing particles in the lung. Secondly, the numerical concentration of fibrous mineral particles containing only aluminium (hereafter referred to as “aluminium fibres”) expressed per millilitre of BAL fluid or per gram of dry lung tissue, and their granulometry (length, diameter, and length/diameter ratio) were determined. No distinction was made between α and γ alumina. Thirdly, the numerical concentration of other fibrous particles, especially asbestos fibres was measured.

Results

Results of the mineralogical analysis in the five patients are presented in Table 1. All but one of the patients had
ceased exposure to aluminium products for at least 4 yrs before collection of the biological sample. No significant retention of asbestos bodies was observed in the four cases in which this retention was studied by light microscopicanalysis. No case exhibited significant conc-
etration of asbestos fibres in BAL fluid or lung tissue using ATEM. A high concentration of nonfibrous mineral particles was observed in the lung tissue samples analysed, with a high percentage of particles containing alumini-
um (40 and 56% in case No. 1 and 2, respectively).

The most striking observation was obtained from TEM analysis of aluminium fibres: the fibres were rather short and thin, with a mean length of about 1–2 \( \mu \)m and no fibres longer than 5 \( \mu \)m. The mean length: diameter ratio of aluminium fibres ranged 8.6–25.6. Elementary chemical analysis with energy dispersive spectrometry (EDS) revealed the presence of aluminium with no other associated elements (fig. 1). The electron diffraction pattern showed that the fibres were crystalline.

No other fibres were observed in lung tissue samples of cases No. 1 and 2, whilst a low concentration of chrysotile fibres was identified in BAL fluid samples of cases Nos. 3, 4 and 5 (6\( \times \)10^5, 9\( \times \)10^5 and 1.7\( \times \)10^5 fibres·mL\(^{-1}\) in cases No. 3, 4 and 5, respectively).
To our knowledge, aluminium fibres are not added at any steps of the process. However, the presence of aluminium fibres in the air of potrooms during primary aluminium production has been reported [26]. One author mentioned the presence of short (mean length 0.87 µm) and thin (mean diameter 0.05 µm) fibres in the work environment in this industry [26]. Energy dispersive X-ray microanalysis revealed that only sodium and aluminium elements were detected. These fibres were, therefore, assumed to be sodium aluminium tetrafluoride fibres. The author suggested that these fibres were produced during recrystallization of fumes from the electrolyte [26].

While aluminium is commonly encountered when analysing mineral particles in BAL fluid or lung tissue, the presence of this mineral in a fibrous form in human lungs has been poorly documented [14]. Gilks and Churg reported a high concentration of aluminium fibres in the lung tissue of a patient with lung fibrosis [14]. They demonstrated these fibres consisted of α-aluminium oxide. They also reported a mean concentration of 7×10^5 aluminium fibres per gram of dry lung in nine reference cases. In our experience, in subjects without any significant occupational exposure to mineral particles (either fibrous particle or NFMP), lung concentration of aluminium fibres was always less than 3.5×10^5 fibres per gram of dry lung tissue (five patients; range of NFMP concentration 0.22×10^6 to 0.38×10^6 particles·g^{-1}) with percentage of aluminium-containing particles less than 2%; range of all fibres concentration: 3.4×10^6 to 5.7×10^6 fibres·g^{-1}; range of mean length of fibres: 0.5 to 0.8 µm; fibres were identified as mullite and chrysotile fibres) (Voisin et al., unpublished data). In BAL fluid, no aluminium fibres were detected (three patients; range of NFMP concentration 0.079×10^6 to 0.12×10^6 particles·mL^{-1}; range of all fibres concentration: 0.25×10^3 to 0.5×10^3 fibres·mL^{-1}; range of mean length of fibres 0.65 to 0.8 µm; fibres were identified as chrysotile fibres). These data are consistent with those reported by Gilks and Churg [14].

In the present series, all five subjects employed in the aluminium industry (four in the primary industry) exhibited levels of aluminium fibre retention much higher than those observed in control subjects. The exact nature of these fibres could not be established but they were different from the short mullite fibres, which are commonly encountered in BAL fluid and lung tissue and are not considered pathogenic to humans [27]. Some elements (such as oxygen, hydrogen or fluorine) could be present in aluminium-containing fibres in these subjects, but our analytical system was unable to detect these elements (as their atomic numbers are all less than 10). However, elemental chemical analysis with EDS also failed to reveal the presence of sodium. We cannot, therefore, confirm that the chemical composition of aluminium-containing fibres was similar to that described by Gyelseth et al. [26], unless sodium was leached in the biological fluid of the respiratory tract. Alternatively, our data are also consistent with various forms of aluminium oxides (such as alumina trihydroxide Al(OH)₃ or crystallized alumina Al₂O₃, either α or γ form). As the fibre parameters are similar to those reported by Gilks and Churg [14], we consider that the most probable fibre composition was

Fig. 1. – Morphological features of aluminium fibres in lung tissue on analytical transmission electron microscopy (ATEM). Characterization of the fibre was based on: a) morphological features; b) typical X-ray energy dispersive spectrum; and c) selected area electron diffraction. Energy location of significantly detected peaks: Al (Kα) 1.49 keV, Cu (Kα, Kβ) 8.04 keV, 8.90 keV The Al peak was attributed to the fibres, Cu from the grid and apparatus. No peak was observed for Na (Kα: 1.04 keV). (Internal scale bar=0.25 µm).
Al$_2$O$_3$. Industrial hygiene measurements should be performed to document the presence of aluminium fibres during the various steps of alumina synthesis.

The concentrations of aluminium nonfibrous particles were also high in these five subjects, largely above mean or median values reported for aluminium-containing NFMP in BAL fluid samples or lung tissue samples of controls in previous series analysed in the same laboratory [18, 19]. The mean value of aluminium-containing NFMP in BAL fluid was 5.6×10$^9$ particles·mL$^{-1}$ (range 0–1.28×10$^4$ particles·mL$^{-1}$) in the first series of 42 controls [19]. Mean values of aluminium-containing NFMP in BAL fluid and lung tissue were 1×10$^4$ particles·g$^{-1}$ dry lung tissue in the second series of 10 patients with aluminosis. The potential pathogenetic role of this high level of aluminium-containing NPMP in the respiratory tract remains open to question.

Only a few cases of parenchymal fibrosis in primary aluminium industry workers have been reported in the recent literature [14, 16]. Older and more controversial data dealing with the fibrogenic potency of aluminium dust were discussed by Waldron [28]. However, in a recent experimental study in rats, using intra-tracheal instillation of various alumina samples, the fibrogenic potency of a chemical-grade alumina sample (different from industrial aluminas) was demonstrated [29]. In contrast, no fibrosis was noted with five other alumina samples used in aluminium production. This was consistent with the results of Tornling et al. [30], who found no histological signs of fibrosis in any of the animals instilled intra-tracheally with alumina dust, either with or without adsorbed fluorides. However, fibronectin concentrations were significantly increased in B AL fluid 1 year after exposure to aluminium dust in animals treated with both alumina dust samples. Data concerning the potential role of aluminium fibres in the development of lung fibrosis in humans are limited to case reports from GILKS and CHURG [14] and fibres in the development of lung fibrosis in humans are possible. Data concerning the potential role of aluminium were significantly increased in BAL fluid 1 year after adsorption of fluorides. However, fibronectin concentrations were significantly increased in BAL fluid 1 year after instillation of alumina dust samples. In the present series, the latency since cessation of exposure ranged from 6 months to 18 yrs, indicating that these aluminium fibres exhibit a certain biopersistence in man. Biopersistence has been shown to be an important parameter in the lung pathogenicity of minerals [32].

In conclusion, this series revealed a significant retention of aluminium fibres in biological samples from subjects working in the aluminium industry. In some subjects, these aluminium fibres remained in the respiratory tract for many years after cessation of exposure suggesting biopersistence of this mineral. The role of these short fibres in the development of parenchymal disease remains open to question and should be documented by further investigations, which should also include industrial hygiene measurements of aluminium particles in the potroom atmosphere at different steps of the process, with determination of granulometric parameters.

Acknowledgements: The authors are indebted to M.A. Bilion-Galland, P. Grill and X. Janson (Laboratoire d’Etude des Particules Inhalées, Paris, France) for excellent technical assistance, and to P Personnet (LRF, Aluminium Pechniey, St Jean de Maurienne, France) for helpful comments about the industrial process. They are also indebted to Y. Aniel (Aiguelongue, France), F. Capron (Hôtel Dieu, Paris, France), P. Chanez (Montpellier, France), M. Dahan (Toulouse, France), B. Fouquet (Calais, France), M.C. Guibert (Aluminium Dunkerque, Looon Plage, France), C. Jambon (Montpellier, France), Y. Laborde (Pau, France), D. Ledaguenel (Bordeaux, France), P. Leophonte (Toulouse, France), F.B. Michel (Montpellier, France), G. Mignonat (Pau, France), G. Neisinger (Mulhouse, France), F. Pellerin (Montpellier, France), D. Robinet (Saint Louis, France), S. Voisin-Saltiel (Corbeil, France) for providing biological samples and clinical information.

References


